Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Malignant Disease × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 758 Lung Neoplasms 339 Ovarian Neoplasms 318 Breast Neoplasms 277 Fallopian Tube Neoplasms 158 Triple Negative Breast Neoplasms 142 Small Cell Lung Carcinoma 137 Neoplasms 134 Squamous Cell Carcinoma of Head and Neck 121 Carcinoma, Ovarian Epithelial 114 Neoplasm Metastasis 84 Head and Neck Neoplasms 79 Endometrial Neoplasms 76 Uterine Cervical Neoplasms 70 Esophageal Neoplasms 70 Adenocarcinoma of Lung 68 Neuroblastoma 55 Central Nervous System Neoplasms 52 Lymphoma, Large B-Cell, Diffuse 49 Carcinoma 48 Brain Neoplasms 48 Recurrence 47 Prostatic Neoplasms 45 Parkinson Disease 4, Autosomal Dominant Lewy Body 44 Urinary Bladder Neoplasms 42 Lymphoma 39 Esophageal Squamous Cell Carcinoma 39 Melanoma 35 Carcinoma, Squamous Cell 33 Lymphoma, Non-Hodgkin 31

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡